Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016

Date: March 31, 2016
Pages: 1436
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M7AD8199611EN
Leaflet:

Download PDF Leaflet

Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016

SUMMARY

GlobalData's clinical trial report, “Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016' provides an overview of Myelodysplastic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Myelodysplastic Syndrome
Mar 24, 2016: Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes Published in Oncotarget
Mar 21, 2016: Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes
Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on SY-1425 in Blood Cancers at Upcoming AACR Annual Meeting
Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting
Mar 09, 2016: Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology
Feb 15, 2016: Phase 3 Study Demonstrates Aranesp (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome
Feb 03, 2016: Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47
Jan 12, 2016: FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies
Jan 11, 2016: Celator Pharmaceuticals Announces Participation in Cardiff University Clinical Trial in Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (AML19)
Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
Clinical Trial Profile Snapshots
Appendix 1433
Abbreviations 1433
Definitions 1433
Research Methodology 1434
Secondary Research 1434
About GlobalData 1435
Contact Us 1435
Disclaimer 1435
Source 1436

LIST OF TABLES

Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2016
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2016
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016

LIST OF FIGURES

Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2016
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016
Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016
Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2016
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2016
Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2016
Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016
Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016
GlobalData Methodology 1434

COMPANIES MENTIONED

Celgene Corporation
Novartis AG
Sanofi
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Onconova Therapeutics, Inc.
Groupe Francophone des Myelodysplasies
Amgen Inc.
Eisai Co., Ltd.
Skip to top


Ask Your Question

Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: